Menu
Svensk version

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

During July, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants and the new issue of shares that was made in connection with the exercise of the over-allotment option, subsequent to the listing of the Company’s shares on Nasdaq Stockholm. As of July 31, 2017, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 49,138,735.

 

 

About BONESUPPORT

 

BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bioceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void. BONESUPPORT’s marketed synthetic bone graft substitutes CERAMENT™ BONE VOID FILLER (BVF), CERAMENT™ G and CERAMENT™ V* are all based on the Company’s novel and proprietary CERAMENT technology platform.

 

The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot. The Company’s research and development is focused on the continuing development and refinement of its existing technology to extend its use into additional indications by the elution of other drugs and therapeutic agents.

 

BONESUPPORT’s products are based on an innovative technology backed by an intellectual property portfolio of approximately 100 registered and/or pending patents. BONESUPPORT has a nine year track record of safety and efficacy in treating patients with an estimated number of 30,000 procedures performed to date with its products worldwide based on sales data.

BONESUPPORT’s total sales increased from SEK 41 million in 2014 to SEK 105 million in 2016, representing a compound annual growth rate of 60 percent.

BONESUPPORT was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist. The Company is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at www.bonesupport.com

*CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States.
BONESUPPORT™ is a registered trademark.  

 

For more information contact:  

Richard Davies, CEO

Tel: +46 (0) 46 286 53 71

 

Björn Westberg, CFO

Tel: +46 (0) 46 286 53 60

Email: ir@bonesupport.com  

 

The information in the press release is such that BONESUPPORT HOLDING AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 18:00 CET on July 31, 2017.

 

Downloads

Press release PDF (119.29 KB)

BONESUPPORT, Mon Aug 7, 2017

BONESUPPORT is a #medtech company dedicated to development of injectable osteoconductive biomaterials https://t.co/SZVyGV3pkq

BONESUPPORT, Fri Aug 4, 2017

BONESUPPORT is a Scandinavian #medtech company dedicated to development of injectable osteoconductive biomaterials, https://t.co/SZVyGULOsS

BONESUPPORT, Tue Jul 4, 2017

BONESUPPORT is a Scandinavian #medtech company dedicated to development of injectable osteoconductive biomaterials, https://t.co/SZVyGULOsS